China Declares Outbreak Past Peak, But Drug Makers Far From Recovery
Good Old Days May Never Return?
Clinical studies in hiatus, marketing on hold, demand directionless and supply disrupted. Pharma firms in China say it’s likely the good old days may never come back.
You may also be interested in...
China's centralized procurement scheme, if further expanded after causing the prices of 32 drugs to be cut by more than half in the latest round, will leave companies no room to breathe easy amid the already devastating coronavirus outbreak, analysts say.
Daily round-up of the latest coronavirus news: Trump's chloroquine mix-up, imported cases rise in China, Biogen sacks employee over China travel, Vir's Scango talks about its COVID-19 efforts, Roche's Actemra study plus COVID-19 pipeline infographic.
A new commissioner has taken the reins at China's National Medical Products Administration, but the senior CCP official has so far given few clear indications about the changes he might bring.